A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

NCT05444972 | Completed

• 1 other identifier: H23-122
• Study Type: observational
• Target: 998
• Locations: 14 countries
• Sites: 66

Brief Summary

Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.

Conditions

Myelofibrosis

Keywords

Myelofibrosis; Cancer

Outcome Measures

Primary Outcomes (4)

• Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment

  Time from diagnosis of MF to initial treatment.

  Up to Week 156

• Duration of Initial Treatment

  Duration of initial treatment.

  Up to Week 156

• Duration of Second Treatment

  Duration of second treatment.

  Up to Week 156

• Duration of Subsequent Treatments

  Duration of subsequent treatments.

  Up to Week 156

Study Arms (1)

Participants Undergoing Chart Review

Participants treated for myelofibrosis undergoing chart review.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult participants patients diagnosed with myelofibrosis and treated on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.

You may qualify if:

• Treated for myelofibrosis (MF) \[primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)\].
• Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.

You may not qualify if:

• \- Having received MF treatment in a clinical trial setting.

Sponsors & Collaborators

• AbbVie: lead

Study Sites (66)

UAB Comprehensive Cancer Center /ID# 252767

Birmingham, Alabama, 35233-1932, United States

Location

Wellness Oncology & Hematology /ID# 255591

West Hills, California, 91307-1468, United States

Location

Brigham & Women's Hospital /ID# 254312

Boston, Massachusetts, 02115, United States

Location

Gabrail Cancer Center Research /ID# 252768

Canton, Ohio, 44718, United States

Location

Instituto FIDES /ID# 245526

La Plata, Buenos Aires, 1900, Argentina

Location

Hospital Italiano de Buenos Aires /ID# 244373

Ciudad Autonoma Buenos Aires, Ciuadad Autonoma de Buenos Aires, 1199, Argentina

Location

Fundaleu /Id# 244371

Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, 1114, Argentina

Location

Townsville University Hospital /ID# 246585

Douglas, Queensland, 4814, Australia

Location

Royal Adelaide Hospital /ID# 246583

Adelaide, South Australia, 5000, Australia

Location

Fiona Stanley Hospital /ID# 246584

Murdoch, Western Australia, 6150, Australia

Location

Royal Perth Hospital /ID# 246586

Perth, Western Australia, 6000, Australia

Location

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 247394

São Paulo, São Paulo, 05652-900, Brazil

Location

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 247392

São Paulo, 05403-000, Brazil

Location

St. Paul's Hospital /ID# 249719

Vancouver, British Columbia, V6Z 1Y6, Canada

Location

Nova Scotia Health /ID# 248393

Halifax, Nova Scotia, B3H 1V7, Canada

Location

Juravinski Cancer Centre /ID# 251334

Hamilton, Ontario, L8V 1C3, Canada

Location

Princess Margaret Cancer Centre /ID# 249748

Toronto, Ontario, M5G 2M9, Canada

Location

CSSS Alphonse-Desjardins, CHAU de Levis /ID# 250449

Lévis, Quebec, G6V 3Z1, Canada

Location

CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 250563

Montreal, Quebec, H1T 2M4, Canada

Location

Jewish General Hospital /ID# 250674

Montreal, Quebec, H3T 1E2, Canada

Location

Organizacion Clinica Bonnadona -PREVENIR S.A.S. /ID# 244589

Baranquilla, Atlántico, 080016, Colombia

Location

Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 246108

Bogota DC, Cundinamarca, 111221, Colombia

Location

Fundacion Santa Fe de Bogota /ID# 244588

Bogota, Cundinamarca, 11011, Colombia

Location

Clínica Imbanaco S.A.S /ID# 248465

Cali, 760042, Colombia

Location

Hospital Pablo Tobon Uribe /ID# 244525

Medellín, 50034, Colombia

Location

General Hospital of Athens Laiko /ID# 246159

Athens, Attica, 11527, Greece

Location

University General Hospital Attikon /ID# 246167

Athens, Attica, 12462, Greece

Location

University General Hospital of Heraklion PA.G.N.I /ID# 246163

Heraklion, Crete, 71500, Greece

Location

General University Hospital of Alexandroupolis /ID# 246161

Alexandroupoli, 68100, Greece

Location

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 246165

Athens, 10676, Greece

Location

University General Hospital of Ioannina /ID# 246160

Ioannina, 45500, Greece

Location

METAXA Cancer Hospital of Piraeus /ID# 246164

Piraeus, 18737, Greece

Location

University General Hospital of Patras /ID# 246162

RION Patras Achaia, 26504, Greece

Location

Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 245149

Cona, Ferrara, 44124, Italy

Location

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 245335

Rome, Lazio, 00168, Italy

Location

Azienda Ospedaliera di Perugia /ID# 245415

Perugia, Umbria, 06129, Italy

Location

IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 245716

Bologna, 40138, Italy

Location

ASST Spedali civili di Brescia /ID# 244910

Brescia, 25123, Italy

Location

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 244909

Milan, 20122, Italy

Location

Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 245566

Novara, 28100, Italy

Location

Azienda Ospedaliera Universitaria Paolo Giaccone /ID# 245075

Palermo, 90127, Italy

Location

ASST Sette Laghi /ID# 245443

Varese, 21100, Italy

Location

Ospedale Belcolle /ID# 245726

Viterbo, 01100, Italy

Location

Hospital de Especialidades CMN SigloXXI /ID# 244748

Mexico City, Mexico City, 06720, Mexico

Location

Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 244750

Monterrey, Nuevo León, 64610, Mexico

Location

Hospital General de Mexico /ID# 244749

Mexico City, 06720, Mexico

Location

Krzysztof Mądry Praktyka Lekarska /ID# 250485

Warsaw, Masovian Voivodeship, 01-309, Poland

Location

Specjalistyczna Praktyka Lekarska Witold Prejzner /ID# 250516

Gdansk, Pomeranian Voivodeship, 80-337, Poland

Location

Joanna Góra-Tybor Specjalistyczna Praktyka Lekarska /ID# 250495

Lodz, 90-712, Poland

Location

Specjalistyczna Praktyka Lekarska Grzegorz Helbig /ID# 250515

Orzesze, 43-180, Poland

Location

Centro Hospitalar e Universitario de Coimbra, EPE /ID# 244687

Coimbra, 3000-075, Portugal

Location

Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 248203

Lisbon, 1649-035, Portugal

Location

Centro Hospitalar Universitario de Sao Joao, EPE /ID# 244400

Porto, 4200-319, Portugal

Location

MedLife - Policlinica de Diagnostic Rapid /ID# 244395

Brasov, Brașov County, 500152, Romania

Location

Spitalul Clinic Colentina /ID# 245620

Bucharest, 020121, Romania

Location

Institutul Clinic Fundeni /ID# 245939

Bucharest, 925200, Romania

Location

Institutul Oncologic Prof Dr I Chiricuta /ID# 244393

Cluj-Napoca, 400015, Romania

Location

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 250092

Kaohsiung City, 807, Taiwan

Location

National Taiwan University Hospital /ID# 250093

Taipei, 100, Taiwan

Location

Gulhane Askeri Tip Academy /ID# 244134

Ankara, 06010, Turkey (Türkiye)

Location

Hacettepe University Medical Faculty /ID# 244131

Ankara, 06230, Turkey (Türkiye)

Location

Dicle Universitesi Tip /ID# 244137

Diyarbakır, 21200, Turkey (Türkiye)

Location

Trakya University Medical Facu /ID# 244132

Edirne, Istanbul, 22030, Turkey (Türkiye)

Location

Bagcilar Medipol Mega Universite Hastanesi /ID# 244133

Istanbul, 34214, Turkey (Türkiye)

Location

Ege University Medical Faculty /ID# 244130

Izmir, 35040, Turkey (Türkiye)

Location

Inonu University Medical Faculty /ID# 244135

Malatya, 44280, Turkey (Türkiye)

Location

Related Publications (1)

• Gupta V, Tomuleasa C, Barranco Lampon GI, Hou HA, Helbig G, Vachhani P, Symeonidis A, Haznedaroglu I, Galvez K, Tatsch F, Chopra AS, Zhang M, Vizkelety T, Murray B, Ross DM. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study. Blood Adv. 2025 Mar 11;9(5):1105-1116. doi: 10.1182/bloodadvances.2024014625.

  PMID: 39729499 DERIVED

MeSH Terms

Conditions

Primary Myelofibrosis; Neoplasms

Condition Hierarchy (Ancestors)

Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• ABBVIE INC.

  AbbVie

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2022
• First Posted: July 6, 2022
• Study Start: August 23, 2022
• Primary Completion: November 14, 2023
• Study Completion: November 14, 2023
• Last Updated: December 11, 2023

Record last verified: 2023-12

Locations

CA (7); BR (2); GR (8); AR (3); AU (4); US (4); IT (10); ME (3); PT (3); TU (7); PL (4); TW (2); RO (4); CO (5)